• Fusobacterium nucleatum EVs Promote CRC Colonization via Mem

  2026-05-15

  This study uncovers how extracellular vesicles (EVs) from Fusobacterium nucleatum accumulate in colorectal cancer (CRC) tissues and facilitate bacterial colonization through membrane fusion and surface transfer of the adhesin FomA. These findings clarify a key mechanism in microbial niche preparation within tumors and offer new directions for endocytosis-focused cancer research.

• Panobinostat Targets Epigenetic Vulnerabilities in MLL-ALL

  2026-05-15

  This study demonstrates that the HDAC inhibitor panobinostat exerts potent anti-leukemic effects in MLL-rearranged acute lymphoblastic leukemia by disrupting H2B ubiquitination via the RNF20/RNF40/WAC axis. The findings highlight a convergence of epigenetic vulnerabilities in aggressive infant ALL and offer insights for developing targeted therapeutic strategies.

• METTL16-SENP3-LTF Axis Drives Ferroptosis Resistance in HCC

  2026-05-14

  Wang et al. delineate a novel METTL16-SENP3-LTF signaling cascade that promotes ferroptosis resistance and tumor growth in hepatocellular carcinoma (HCC) by controlling iron metabolism at the post-transcriptional level. Their findings spotlight a targetable molecular pathway for sensitizing HCC to ferroptosis, with implications for future therapeutic strategies.

• Nicotine Signaling Accelerates CKD Progression: Mechanistic

  2026-05-14

  Jain and Jaimes (2013) provide a comprehensive mechanistic review revealing how nicotine signaling, through non-neuronal nicotinic acetylcholine receptors in the kidney, accelerates chronic kidney disease (CKD) progression among smokers. Their synthesis of clinical and experimental data highlights oxidative stress and pro-fibrotic pathways as central mediators, suggesting new molecular intervention points for CKD research.

• α-Amanitin in Functional Transcriptomics: Precision and Pitf

  2026-05-13

  Explore the nuanced application of α-Amanitin as a benchmark RNA polymerase II inhibitor for cutting-edge transcriptional regulation research. This article delivers advanced assay guidance, highlights protocol caveats, and uniquely integrates insights from post-transcriptional epigenetics.

• CUDC-907: Technical Protocols for Dual PI3K and HDAC Inhibit

  2026-05-13

  CUDC-907 offers researchers a practical approach to simultaneous inhibition of class I PI3K isoforms and select HDACs in established cancer cell models. It is strictly intended for controlled laboratory workflows and not for diagnostic, therapeutic, or clinical use.

• EZ Cap™ Firefly Luciferase mRNA: Optimizing Reporter Assays

  2026-05-12

  EZ Cap™ Firefly Luciferase mRNA with Cap 1 structure unlocks next-level sensitivity and stability for bioluminescent reporter assays in both in vitro and in vivo contexts. This article delivers actionable workflow enhancements and troubleshooting strategies, grounded in recent advances in lipid nanoparticle delivery and mRNA engineering.

• P2Y11 Antagonist NF 340: Applied Workflows in Cancer & Immun

  2026-05-12

  NF 340, a selective P2Y11 antagonist from APExBIO, empowers researchers to precisely dissect GPCR signaling and inflammation pathways in advanced oncology and immunology models. This article delivers real-world protocols, troubleshooting insights, and evidence-driven rationale for integrating NF 340 into translational research workflows.

• Auranofin as a Thioredoxin Reductase Inhibitor in Cancer Wor

  2026-05-11

  Auranofin's nanomolar potency as a thioredoxin reductase inhibitor enables precise modulation of redox balance, apoptosis, and radiosensitivity in tumor models. This guide delivers protocol-ready parameters, troubleshooting advice, and experimental insights for researchers seeking reproducible outcomes in cancer and mechanotransduction studies.

• Protease Inhibitor Cocktail EDTA-Free: Ensuring Protein Inte

  2026-05-11

  Discover how the Protease Inhibitor Cocktail EDTA-Free (100X in DMSO) empowers advanced protein extraction and signaling studies. This article uniquely explores its decisive role in preserving protein integrity during challenging workflows, including cutting-edge mitochondrial research.

• Deferasirox: Oral Iron Chelator Enabling Precision Cancer Re

  2026-05-10

  Deferasirox is revolutionizing iron chelation workflows, offering both robust iron overload management and targeted disruption of tumor iron metabolism. Its unique properties streamline apoptosis and ferroptosis studies, with APExBIO providing high-purity, research-ready product for reproducible results.

• Host Actin–Myosin II Network Regulates DEV Proliferation via

  2026-05-09

  This study reveals that the duck enteritis virus protein VP26 interacts with host actin–myosin II cytoskeletal components, particularly MYH9, to regulate viral proliferation. Through proteomic screening and functional assays—including actin polymerization inhibition—the work establishes the host cytoskeleton as a crucial determinant of DEV replication, offering mechanistic insight for cell biology and virology research.

• 2,5-di-tert-butylbenzene-1,4-diol: Transforming Calcium Sign

  2026-05-08

  2,5-di-tert-butylbenzene-1,4-diol (BHQ) empowers researchers to dissect SERCA-dependent calcium homeostasis and stem cell mobilization with unprecedented precision. Optimized for both mechanistic assays and translational workflows, BHQ from APExBIO sets a new standard for experimental reliability and protocol flexibility.

• Transcription Termination Limits DNA Damage After WEE1 Inhib

  2026-05-08

  This article reviews how transcription termination constrains DNA damage and cell death following WEE1 inhibition, based on recent findings by Landsverk et al. The study elucidates the molecular interplay between replication stress, transcription-replication conflicts, and genome stability, with direct implications for optimizing targeted cancer therapies.

• Losmapimod (GW856553X): Next-Gen p38 MAPK Modulation Unveile

  2026-05-07

  This article provides translational researchers with an evidence-rich, mechanistically-driven perspective on Losmapimod (GW856553X) as a dual-action p38 MAPK inhibitor, highlighting emerging insights into kinase-phosphatase interplay, strategic study design, and clinical relevance for inflammation and vascular research. It leverages recent mechanistic breakthroughs—specifically the ability of certain inhibitors to both block kinase activity and promote dephosphorylation—to shape future research directions and experimental best practices.

16358 records 1/1091 page Next 12345 下5页 Last page